Tissue Expression of Krüppel-Like Factors 4 and 7 in Bone Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-08-16

Study Completion Date

2026-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The current study is to assess the prognostic value of Krüppel-like factors 4 and 7 in bone tumors, and its role in the disease progression.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Biomarker Expression in Tissue Samples From Patients With Bone Sarcomas

NCT01807052

Localized Osteosarcoma Metastatic Osteosarcoma Recurrent Osteosarcoma

COMPLETED

Cancer in Infants: South Egypt Cancer Institute Experience

NCT02668354

Infantile Neoplasms

UNKNOWN

Prognostic Biomarkers in Tumor Tissue Samples From Young Patients With Neuroblastoma

NCT01358617

Disseminated Neuroblastoma Localized Resectable Neuroblastoma Localized Unresectable Neuroblastoma +2 more

COMPLETED

Assessment of Bmi-1 on Protein and Molecular Levels in Oral Dysplasia and Squamous Cell Carcinoma: A Diagnostic Study

NCT03345966

Oral Squamous Cell Carcinoma

UNKNOWN NA

The Prognostic Value of Serum Biomarkers in Osteosarcoma

NCT05093101

Osteosarcoma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Krüppel-like factors are a group of proteins that engage in different cell functions including proliferation, apoptosis, autophagy, invasion, and migration, and have been discovered to play an important role in bone disease development.

Study Setting: Pediatric Hematology, Oncology and Bone Marrow Transplantation Unit at Ain Shams University Children's Hospital.

* Type of Study: Prospective cohort.
* Study Period: 12 months.
* Study Population: Children, adolescents, and young adults diagnosed with localized and metastatic both skeletal and extra-skeletal osteosarcoma and Ewing's sarcoma
* Sampling Method: Convenience
* The medical history by direct interview of participants or from the patients files with a focus on:

* Symptoms such as pain, swelling, and fracture including duration, intensity, and timing of complaint.
* Specific events for bone tumors include prior benign/malignant lesions, family history, and previous radiotherapy for a prior cancer.
* Assessment of the adverse outcomes.
* Treatment protocol, timing of local control, type of local surgical control, need for adjuvant or definitive radiation therapy.
* Examination carried out upon initial patients' presentation (collected from files in the historical group):

* A full physical examination including weight and height, with calculation of body mass index (BMI) and surface area (SA).
* Local examination with specific attention to the size, consistency of the swelling, its location and mobility, the relation of swelling to the involved bone, and the presence of regional/ local lymph nodes.
* Radiologic investigations at initial diagnosis, after induction chemotherapy, after local control, as well as at the end of therapy and every 3 months during 1st 2 years after therapy (collected from files in the historical group):

* Conventional radiographs in two planes
* Magnetic resonance imaging (MRI) of the whole compartment with adjacent joints,
* Computed tomography (CT) should be used only in the case of diagnostic problems or doubt, to visualize more clearly calcification, periosteal bone formation, or cortical destruction
* Stage classification: positron emission tomography (PET)/CT using General Electric device number 5632.
* Laboratory assessment at presentation for cohort group (collected from files in the historical group)

* Complete blood count (CBC)
* Electrolytes including serum Calcium, phosphorus, magnesium, bicarbonate; creatinine, blood urea nitrogen, liver enzymes, and lactate dehydrogenase (LDH)
* Pathological methods:

* Histopathological examination of H\&E-stained sections prepared from paraffin blocks at 4-5 um thickness.
* Immunohistochemical staining of 4 um sections prepared from paraffin blocks using KLF factor (4 and 7); this will be done with automated immunostaining using the streptavidin-biotin technique.
* Interpretation of the stained slides will be done using a semiquantitative score and the results will be statistically analyzed.
* Sample Size: 30 patients

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteosarcoma in Children Ewing Sarcoma of Bone or Soft Tissue

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Prospective Arm

Children, young adolescents younger than 15 years, and young adults (15 to 39 years) with histologically confirmed patients with skeletal or extra-skeletal OS or ES with localized or metastatic disease stages.

KLF factor (4 and 7)

Intervention Type DIAGNOSTIC_TEST

Immunohistochemical staining of 4 um sections prepared from paraffin blocks using KLF factor (4 and 7) by automated immunostaining using the streptavidin-biotin technique.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

KLF factor (4 and 7)

Immunohistochemical staining of 4 um sections prepared from paraffin blocks using KLF factor (4 and 7) by automated immunostaining using the streptavidin-biotin technique.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Age: children, young adolescents younger than 15 years, and young adults (15 to 39 years) Gender: Males and female. Histologically confirmed patients with skeletal or extra-skeletal OS or ES. Both localized and metastatic disease stages.